Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: a multi-center Phase 2 Study
      QxMD      Google Scholar   
Citation:
Lancet Oncol vol 12 (4) 361-368
Year:
2011
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Book Volume:
Parents:
2267  
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
R01 CA092104, R01 CA092104-07, CA92104, CA25224, U10 CA025224, U10 CA025224-26  
Corr. Author:
 
Authors:
                         
Primary Study
N038H
Secondary Studies:
Phases:
2
Keywords:
Mantle Cell Lymphoma, mTOR Inhibitor, Rituximab, Phase 2 Trial